Tengchong Pharmaceutical

Brii Biosciences is a clinical-stage biotechnology company dedicated to developing innovative therapies for infectious diseases and central nervous system (CNS) disorders. The company's primary focus is on addressing major public health challenges, particularly in China and globally, by advancing a pipeline of potential best-in-class and first-in-class medicines. Their lead programs target chronic hepatitis B virus (HBV) infection, utilizing a combination of siRNA and therapeutic vaccines to achieve a functional cure. Additionally, Brii has successfully developed and commercialized antibody treatments for COVID-19 and is progressing candidates for postpartum depression and multi-drug resistant bacterial infections. The company operates with a global footprint, maintaining significant R&D and corporate presence in both the United States and China.